Amygdala Neurosciences Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$2M
- Investors
-
4
Amygdala Neurosciences General Information
Description
Developer of a biopharmaceutical technology intended to focus on the large and growing unmet need associated with substance use disorders. The company's technology uses a selective ALDH2 inhibitor that prevents a surge in dopamine levels and associated cravings without changes to basal dopamine, enabling patients to quit and get rid of their addiction to drugs, alcohol, and smoking.
Contact Information
Website
www.amygns.comCorporate Office
- 5214F Diamond Heights Boulevard
- Suite 151
- San Francisco, CA 94131
- United States
Corporate Office
- 5214F Diamond Heights Boulevard
- Suite 151
- San Francisco, CA 94131
- United States
Amygdala Neurosciences Timeline
Amygdala Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Grant | 01-Aug-2023 | $2M | Completed | Pre-Clinical Trials | ||
| 7. Grant | 10-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 6. Seed Round | 28-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 21-Oct-2019 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 19-Sep-2018 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 19-May-2017 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 10-Feb-2017 | $2M | $3.45M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 10-Apr-2015 | $1.45M | $1.45M | Completed | Pre-Clinical Trials |
Amygdala Neurosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 4,340,673 | $0.000100 | $0.03 | $0.55 | $0.55 | 1x | $0.5 | 11.97% |
| Seed-1 | 5,307,464 | $0.000100 | $0.02 | $0.27 | $0.27 | 1x | $0.27 | 13.24% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Amygdala Neurosciences Comparisons
Industry
Financing
Details
Amygdala Neurosciences Competitors (54)
One of Amygdala Neurosciences’s 54 competitors is Mitobridge, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mitobridge | Formerly VC-backed | Cambridge, MA | ||||
| Alkahest | Formerly VC-backed | San Carlos, CA | ||||
| Astrocyte Pharma | Venture Capital-Backed | Groton, CT | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA |
Amygdala Neurosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amygdala Neurosciences Patents
Amygdala Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023292243-A1 | Aldh-2 inhibitor compounds and methods of use | Pending | 14-Jun-2022 | ||
| AU-2023295214-A1 | Aldh-2 inhibitor compounds and methods of use | Pending | 14-Jun-2022 | ||
| EP-4540228-A1 | Aldh-2 inhibitor compounds and methods of use | Pending | 14-Jun-2022 | ||
| EP-4540237-A1 | Aldh-2 inhibitor compounds and methods of use | Pending | 14-Jun-2022 | ||
| US-12018009-B2 | Aldh-2 inhibitor compounds and methods of use | Active | 14-Jun-2022 | C07D401/04 |
Amygdala Neurosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amygdala Neurosciences Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| Altamont Pharmaceutical Holdings | Holding Company | Minority | ||
| Asset Management Ventures | Venture Capital | Minority | ||
| National Institute of Alcohol Abuse and Alcoholism | Government |
Amygdala Neurosciences Investments (1)
Amygdala Neurosciences’s most recent deal was a Corporate Asset Purchase with Gilead Sciences (GS-6637). The deal was made on 16-Feb-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Gilead Sciences (GS-6637) | 16-Feb-2017 | Corporate Asset Purchase | Buildings and Property |
Amygdala Neurosciences FAQs
-
When was Amygdala Neurosciences founded?
Amygdala Neurosciences was founded in 2015.
-
Where is Amygdala Neurosciences headquartered?
Amygdala Neurosciences is headquartered in San Francisco, CA.
-
What is the size of Amygdala Neurosciences?
Amygdala Neurosciences has 3 total employees.
-
What industry is Amygdala Neurosciences in?
Amygdala Neurosciences’s primary industry is Drug Discovery.
-
Is Amygdala Neurosciences a private or public company?
Amygdala Neurosciences is a Private company.
-
What is Amygdala Neurosciences’s current revenue?
The current revenue for Amygdala Neurosciences is .
-
How much funding has Amygdala Neurosciences raised over time?
Amygdala Neurosciences has raised $10.1M.
-
Who are Amygdala Neurosciences’s investors?
National Institutes of Health, Altamont Pharmaceutical Holdings, Asset Management Ventures, and National Institute of Alcohol Abuse and Alcoholism have invested in Amygdala Neurosciences.
-
Who are Amygdala Neurosciences’s competitors?
Mitobridge, Alkahest, Astrocyte Pharma, Aro Biotherapeutics, and Alzheon are some of the 54 competitors of Amygdala Neurosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
